Repligen: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Repligen (NASDAQ:RGEN) announced record quarterly revenue of over $209 million as bioprocessing demand recovered. The bioprocess equipment manufacturer is expanding into high-growth cell therapy while securing long-term service contracts that lock in recurring demand. Three things management said stand out.

1. BioLife Deal Broadens Cell Therapy Reach

Repligen closed its purchase of BioLife, a cell therapy tools provider, to capture share in advanced treatments. Management expects the unit to generate $24 million in revenue during the fourth quarter.

This combination further expands our capabilities in the rapidly growing cell therapy end market, and strengthens our long term growth platform.
-- Olivier Loeillot, President and Chief Executive Officer

2. Capital Equipment Orders Hit Five-Year High

While capital equipment revenue lagged, demand for bioprocessing machinery rebounded as customers placed new orders. These commitments build a multi-year backlog that sets up sales growth for 2027.

Capital equipment orders increased mid-teens year-over-year and was the highest orders quarter in 5 years while revenue declined.
-- Olivier Loeillot, President and Chief Executive Officer

3. Service Contracts Build Recurring Revenue Base

Repligen is expanding its maintenance and technical services segment to deepen relationships with biopharmaceutical producers. Servicing active machinery provides reliable cash flows and visibility into customer equipment usage.

Year to date, our services team has increased the number of systems under contract by nearly 40% despite a muted capital equipment revenue environment.
-- Olivier Loeillot, President and Chief Executive Officer

Looking Ahead

Bioprocessing demand is accelerating across pharmaceutical accounts as order books rebuild. Repligen leverages high switching costs in process analytical technology, which measures real-time drug quality, while management prioritizes pricing discipline and international expansion.

Assuming the market is growing high-single-digits, and with the accretion of BioLife, we are positioned to grow our reported top line at least 25% next year, absent a material change in foreign exchange rates.
-- Olivier Loeillot, President and Chief Executive Officer

Operational integration and commercial efficiencies set up long-term revenue targets.

With the addition of BioLife and the strategic investment we are making across our entire portfolio and all regions, we are extremely well positioned to capitalize on the growth opportunities ahead of us.
-- Olivier Loeillot, President and Chief Executive Officer

The Motley Fool recommends Repligen. The Motley Fool has a disclosure policy.